Autologous cultured kidney tissue cells - RegenMedTX

Drug Profile

Autologous cultured kidney tissue cells - RegenMedTX

Alternative Names: Autologous cultured kidney tissue cells - Tengion; Autologous Neo-Kidney augment; Neo-Kidney Augment; Neo-kidney-augment; NKA

Latest Information Update: 28 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tengion
  • Developer RegenMedTX
  • Class Cell therapies
  • Mechanism of Action Cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Kidney disorders

Most Recent Events

  • 28 Jul 2018 No recent reports of development identified for phase-I development in Kidney-disorders in Sweden (Parenteral, Implant)
  • 25 Apr 2018 inRegen initiates a phase II trial for Kidney disorders in USA (Parenteral) (NCT03270956)
  • 05 Sep 2017 inRegen plans a phase II trial for Kidney disorders in USA (NCT03270956)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top